Nuvectis Pharma Inc (NVCT) Stock Analysis
Verdict: HOLD
Strong insider buying and a 2027 cash runway support the bull case for NXP800, though binary clinical risk and 31x P/B limit safety.
Investment score: 62/100
Analysis as of
Is Nuvectis Pharma Inc stock worth reviewing? The TradeMates thesis
NVCT is a speculative oncology play supported by aggressive insider purchases and a refreshed $33 price target, despite zero revenue and high P/B.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 45/100 (weight 15%)
- Technical Momentum: 65/100 (weight 15%)
- Earnings Quality: 50/100 (weight 15%)
- Insider Sentiment: 95/100 (weight 10%)
- Analyst Consensus: 90/100 (weight 10%)
- Risk-Adjusted Return: 60/100 (weight 15%)
Nuvectis Pharma Inc opportunities and risks
What speaks for NVCT
- Exceptional Insider Conviction
What speaks against NVCT
- Binary Clinical Failure
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| NVCT | n/a | 0.0x | n/a | 0.0% | 0.0% | -3.6% |
| ACHV | n/a | 0.0x | n/a | 0.0% | 0.0% | -6.9% |
| STTK | n/a | 336.8x | n/a | -843.8% | -4987.4% | -12.3% |
| MDXG | 20.2x | 1.6x | 8.3x | 81.0% | 7.9% | 10.6% |
| EIKN | n/a | 0.0x | n/a | 0.0% | 0.0% | -398.2% |
| ALT | n/a | 7649.0x | n/a | -41519.4% | -253002.8% | -26.0% |
| Peer median | n/a | 1.6x | n/a | 0.0% | 0.0% | -12.3% |
Frequently asked questions about Nuvectis Pharma Inc (NVCT)
Is NVCT stock a good investment?
The TradeMates model rates Nuvectis Pharma Inc as HOLD with an investment score of 62/100. NVCT is a speculative oncology play supported by aggressive insider purchases and a refreshed $33 price target, despite zero revenue and high P/B. This is algorithmic model output, not personal investment advice.
Is NVCT stock a buy?
The TradeMates model verdict for NVCT is HOLD with an investment score of 62/100. Treat this as a model signal to review, not a personal buy recommendation.